Sugi Predict

Sugi Predict / Compounds / SCHEMBL101528

SCHEMBL101528

SCHEMBL101528

C[Si](C)(C)CCOCn1ccc2c(Br)ccnc21

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 2/20 0.40
▸ NPC1 O15118 1/20 0.32
▸ MAPT P10636 1/20 0.31
▸ MGAM O43451 2/20 0.31
▸ GAA P10253 2/20 0.31
▸ SI P14410 2/20 0.31
▸ MGAM2 Q2M2H8 2/20 0.31
▸ DUT P33316 1/20 0.30
▸ EGFR P00533 1/20 0.30
▸ IGF1R P08069 1/20 0.30
▸ SRC P12931 1/20 0.30
▸ FLT4 P35916 1/20 0.30
▸ KDR P35968 1/20 0.30
▸ FLT3 P36888 1/20 0.30
▸ EPHB4 P54760 1/20 0.30
▸ TEK Q02763 1/20 0.30
▸ AMY1A P0DUB6 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29514152 1.00 DGAT1 (0.40) DGAT1NPC1MAPTMGAMGAA
SCHEMBL21632481 0.84 DGAT1 (0.36) DGAT1NPC1MAPT
SCHEMBL2884544 0.84 DGAT1 (0.35) DGAT1NPC1MAPTDUTEGFR
SCHEMBL29940970 0.84 DGAT1 (0.37) DGAT1NPC1MAPTDUTEGFR
SCHEMBL31710459 0.84 DGAT1 (0.35) DGAT1NPC1MAPTDUTEGFR
SCHEMBL352030 0.84 FGFR1 (0.35) DGAT1NPC1MAPTDUTEGFR
SCHEMBL13521539 0.84 DGAT1 (0.35) DGAT1NPC1MAPTDUTEGFR
SCHEMBL29854726 0.84 FGFR1 (0.35) DGAT1NPC1MAPTDUTEGFR
SCHEMBL100427 0.83 DGAT1 (0.34) DGAT1NPC1MAPT
SCHEMBL17400916 0.83 MGAM (0.30) MGAMGAASIMGAM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250177382-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2025-06-05 — — US disclosed
US-20240400551-A1 NEK7 INHIBITORS HALIA THERAPEUTICS INC (US) 2024-12-05 — — US disclosed
US-20240327412-A1 FACTOR XIIA INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2024-10-03 — — US disclosed
EP-4400172-A2 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS Incyte Holdings Corporation (US) 2024-07-17 — — EP disclosed
EP-3630116-B1 TETRAHYDROPYRIDO[4,3-D]PYRIMIDINE INHIBITORS OF ATR KINASE UNIV TEXAS (US) 2024-05-01 — — EP disclosed
EP-4182322-B1 PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS CHIESI FARM SPA (IT) 2024-04-24 — — EP disclosed
US-20240116947-A1 PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-04-11 — — US disclosed
EP-4036088-B1 PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS INCYTE HOLDINGS CORP (US) 2024-04-03 — — EP disclosed
EP-4294798-A1 FACTOR XIIA INHIBITORS Kalvista Pharmaceuticals Limited (GB) 2023-12-27 — — EP disclosed
WO-2023226822-A1 METHOD FOR USING AZETIDINE DERIVATIVE TO TREAT VIRAL INFECTIONS AND USE 四川科伦博泰生物医药股份有限公司 2023-11-30 — — WO disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 — — US disclosed
EP-2348023-A1 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors Incyte Corporation (US) 2011-07-27 — — EP disclosed
EP-2343299-A1 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors Incyte Corporation (US) 2011-07-13 — — EP disclosed
EP-2343298-A1 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors Incyte Corporation (US) 2011-07-13 — — EP disclosed
US-20100022522-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS Incyte Corporationn, a Delaware corporation 2010-01-28 — — US disclosed
US-7598257-B2 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors INCYTE CORPORATION (US) 2009-10-06 — — US disclosed
US-20090181959-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-07-16 — — US disclosed
EP-1966202-A1 HETEROARYL SUBSTITUTED PYRROLOÝ2,3-B¨PYRIDINES AND PYRROLOÝ2,3-B¨PYRIMIDINES AS JANUS KINASE INHIBITORS Incyte Corporation (US) 2008-09-10 — — EP disclosed
WO-2007070514-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3-B]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION (US) 2007-06-21 — — WO disclosed
US-20070135461-A1 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer INCYTE CORPORATION 2007-06-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116947-A1 PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS TGFBR1, ACVR1, TGFBR2 DGAT1 3459/4885NPC1 2755/4885MAPT 2978/4885
US-20240327412-A1 FACTOR XIIA INHIBITORS F11, F13B, F12 DGAT1 4096/4885NPC1 3064/4885MAPT 4462/4885
US-20250177382-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 DGAT1 4536/4885NPC1 109/4885MAPT 1309/4885
US-20070135461-A1 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer JAK1, JAK3, MAP3K4 DGAT1 3393/4885NPC1 4408/4885MAPT 3688/4885
US-20110201599-A1 CDK Modulators CDK3, CDK1, CDKL1 DGAT1 3881/4885NPC1 4499/4885MAPT 2120/4885
US-20100022522-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK3, JAK1, JAK2 DGAT1 4526/4885NPC1 4797/4885MAPT 3547/4885
US-20090181959-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK3, JAK1, JAK2 DGAT1 4526/4885NPC1 4797/4885MAPT 3547/4885
US-20240400551-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 DGAT1 4708/4885NPC1 131/4885MAPT 1535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.